Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger
Nov. 26, 2024
Biotech Startups and Venture Capital Reporter
Recursion Pharmaceuticals, one of the most advanced companies using artificial intelligence and machine learning tools to expedite drug development, laid off employees after closing a merger last week.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$20
for 3 months, then $399/year
$20 for 3 months Get StartedThen $399/year
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe Log In Artificial intelligence, biotechnology, drug development, health tech, STAT+ Submit a correction requestReprints
Newsletter
Your morning rundown of the science, politics, and money driving biotech today
